AbbVie Inc. 8-K Filing Report: Key Financial Insights & Debt Overview

Here are the key points extracted from the provided financial report section:

1. Entity Information:

• Company Name: AbbVie Inc.
• SEC CIK Number: 0001551152
• SEC Central Index Key (CIK): 0001551152
• Address: 1 North Waukegan Road, North Chicago, IL 60064-6400
• Contact Number: 847-932-7900

2. Filing Details:

• Filing Type: 8-K
• Filing Date: January 6, 2025

3. Stock and Debt Information:

• Common Stock:
• • Par Value: $0.01
  • Ticker Symbol: ABBV
  • Exchange: NYSE (XNYS)
    
• Senior Notes:
• • 0.750% Senior Notes due 2027 (Ticker: ABBV27) - NYSE
  • 2.125% Senior Notes due 2028 (Ticker: ABBV28) - NYSE
  • 2.625% Senior Notes due 2028 (Ticker: ABBV28B) - NYSE
  • 2.125% Senior Notes due 2029 (Ticker: ABBV29) - NYSE
  • 1.250% Senior Notes due 2031 (Ticker: ABBV31) - NYSE

4. Context:

• The financial data pertains to multiple segments, including common stock and various classes of senior notes, with all periods specified starting and ending on January 6, 2025.

5. Exchange Listings:

• The common stock, as well as all listed senior notes, are traded on the NYSE.

Insights:

• AbbVie Inc. is actively maintaining its presence in both equity and debt markets.
• The company has several classes of senior notes, indicating a structured approach to debt financing with varying maturities and interest rates.
• The 8-K filing suggests that there may be significant updates or events concerning the company as of the filing date, which could be relevant for investors and stakeholders.

This information can be critical for investors assessing AbbVie’s financial health, investment opportunities, and risk profile.